Evolution in management of testicular seminoma: Population-based outcomes with selective utilization of active therapies

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 808-814

  Kollmannsberger, C ^a   Tyldesley, S ^a   Moore, C ^b   Chi, K N ^a   Murray, N ^a   Daneshmand, S ^c   Black, P ^d   Duncan, G ^a   Hayes Lattin, B ^e   Nichols, C ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b EARLE A CHILES RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Active surveillance; Chemotherapy; Radiation; Seminoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; DISSEMINATED CANCER; DRUG FATALITY; DRUG MEGADOSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEMINOMA; STROKE; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 79953324912     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq466     Document Type: Article

References (21)

1. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496.
2. Duran I, Sturgeon JF, Jewett MA et al. Initial versus recent outcomes with a nonrisk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT). J Clin Oncol 2007; 25(18S) (Abstr 5021).
3. Kollmannsberger C, Moore C, Chi KN et al. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2009; 21: 1296-1301.
4. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008; 53: 497-513.
5. Powles TB, Bhardwa J, Shamash J et al. The changing presentation of germ cell tumours of the testis between 1983 and 2002. BJU Int 2005; 95: 1197-1200.
6. Warde P, Gospodarowicz M. Evolving concepts in stage I seminoma. BJU Int 2009; 104: 1357-1361.
7. Mead G. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
8. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
9. Aparicio J, Germa JR, Garcia del Muro X et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 2005; 23: 8717-8723.
10. Chung P, Mayhew LA, Warde P et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol) 2010; 22: 6-16.
11. Chung PW, Daugaard G, Tyldesley S et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 2010; 28: 15s (Suppl; Abstr 4535).
12. Tyldesley S, Voduc D, McKenzie M et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology 2006; 67: 594-598.
13. Cummins S, Yau T, Huddart R et al. Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 2009 [Epub ahead of print].
14. Wood L, Kollmannsberger C, Jewett M et al. Canadian consensus guidelines for the management of testicular germ cell cancer. CUAJ 2010; 4: e19-e38.
15. Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181: 627-632.
16. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-1439.
17. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
18. van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24: 467-475.
19. Warde P, Gospodarowicz M, Panzarella T et al. Management of stage II seminoma. J Clin Oncol 1998; 16: 290-294.
20. Garcia-del-Muro X, Maroto P, Guma J et al. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008; 26: 5416-5421.
21. Fossa SD, Oldenburg J, Dahl AA. Short- and long-term morbidity after treatment for testicular cancer. BJU Int 2009; 104: 1418-1422.